JSC “Rafarma” is an integrated pharmaceutical production site designed and operating in compliance with the requirements of the GMP EU. “Rafarma” project is an implementation of the Strategy “Pharma 2020”. It is on the List of perspective projects in the pharmaceutical and medical industry of Ministry of Industry and Trade RF.
In the company's own product portfolio, 16 items of high-tech medicines from the list of VED are antibiotics, cytostatics, oral hypoglycemic drugs, cardiovascular, antituberculous and other drugs in 15 medicinal forms.
Integrated manufacturing cycle of cephalosporins, antibiotics non-β-lactam, antineoplastics and medicines of other pharmacological groups is carried out in 5 separate sections. They are equipped with closed water-treatment systems and closed-circuit ventilation.
Home based R&D facilities carry out autonomous research activities and develop original medicines. The pilot plant is located in the Category “D” rooms to develop industrial prototypes of medicines for clinical trials and pharmacological monitoring, scale R&D developments and work out the technology for industrial production of new products.